Global Irritable Bowel Syndrome Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Mechanism Of Action;

Guanylate Cyclase Receptor-C Agonist, 5HT3 Antagonist, Chloride Channel Activator, and Others.

By Dosage Form;

Solid and Liquid.

By Indication;

IBS-C and IBS-D.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn852583821 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Irritable Bowel Syndrome Market (USD Million), 2021 - 2031

In the year 2024, the Global Irritable Bowel Syndrome Market was valued at USD 3,312.12 million. The size of this market is expected to increase to USD 7,367.93 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.1%.

The global irritable bowel syndrome (IBS) market encompasses various pharmaceuticals, therapies, and diagnostic tools aimed at managing the symptoms and improving the quality of life for individuals affected by this gastrointestinal disorder. IBS is characterized by abdominal pain, bloating, diarrhea, and constipation, affecting millions of people worldwide.

The market for IBS treatments continues to evolve with ongoing research and development efforts focused on novel therapeutic approaches, including medications targeting bowel motility, pain modulation, and gut microbiota. Additionally, dietary modifications, lifestyle interventions, and psychological therapies play significant roles in managing IBS symptoms, contributing to the multifaceted nature of the market.

Key factors driving the growth of the global IBS market include increasing awareness of the condition, growing patient population, and advancements in diagnostic techniques that enable more accurate diagnosis and personalized treatment approaches. Moreover, the rising prevalence of gastrointestinal disorders, coupled with the growing demand for effective symptom management strategies, further propels market expansion.

The competitive landscape of the global IBS market includes pharmaceutical companies, biotechnology firms, medical device manufacturers, and diagnostic companies striving to develop innovative products and solutions to address the unmet needs of IBS patients. Collaboration between healthcare providers, researchers, and industry stakeholders remains crucial in advancing the understanding and management of IBS, ultimately improving patient outcomes and quality of life.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Mechanism Of Action
    2. Market Snapshot, By Dosage Form
    3. Market Snapshot, By Indication
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Irritable Bowel Syndrome Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Irritable Bowel Syndrome (IBS)
        2. Growing Awareness and Diagnosis
        3. Advancements in Treatment Options
      2. Restraints
        1. Lack of Definitive Diagnostic Tests
        2. Limited Efficacy of Current Treatment Options
        3. High Cost of Treatment
      3. Opportunities
        1. Development of Personalized Therapies
        2. Expansion of Over-the-Counter (OTC) Market
        3. Emerging Markets and Untapped Patient Population
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Irritable Bowel Syndrome Market, By Mechanism Of Action, 2021 - 2031 (USD Million)
      1. Guanylate Cyclase Receptor-C Agonist
      2. 5HT3 Antagonist
      3. Chloride Channel Activator
      4. Others
    2. Global Irritable Bowel Syndrome Market, By Dosage Form, 2021 - 2031 (USD Million)
      1. Solid
      2. Liquid
    3. Global Irritable Bowel Syndrome Market, By Indication, 2021 - 2031 (USD Million)
      1. IBS-C
      2. IBS-D
    4. Global Irritable Bowel Syndrome Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Actavis
      2. Astellas Pharma
      3. Nestl
      4. Takeda Pharmaceuticals
  7. Analyst Views
  8. Future Outlook of the Market